Compare IDYA & CRVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IDYA | CRVL |
|---|---|---|
| Founded | 2015 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | 2019 | 1995 |
| Metric | IDYA | CRVL |
|---|---|---|
| Price | $31.40 | $54.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 16 | 0 |
| Target Price | ★ $51.21 | N/A |
| AVG Volume (30 Days) | ★ 824.6K | 189.9K |
| Earning Date | 05-05-2026 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.90 | N/A |
| EPS | N/A | ★ 1.53 |
| Revenue | $218,710,000.00 | ★ $895,589,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $191.08 | N/A |
| P/E Ratio | ★ N/A | $35.03 |
| Revenue Growth | ★ 3024.43 | 12.61 |
| 52 Week Low | $13.45 | $44.83 |
| 52 Week High | $39.28 | $117.70 |
| Indicator | IDYA | CRVL |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 52.86 |
| Support Level | $29.15 | $50.51 |
| Resistance Level | $35.47 | $55.46 |
| Average True Range (ATR) | 1.47 | 1.89 |
| MACD | -0.26 | 0.31 |
| Stochastic Oscillator | 30.38 | 74.63 |
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
CorVel Corp applies technology including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. It partners with employers, third-party administrators, insurance companies, and government agencies in managing worker's compensation and health, auto, and liability services. The company's solutions combine integrated technologies with a human touch providing services that include claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care, and medicare services.